Ignite Creation Date:
2025-12-24 @ 1:59 PM
Ignite Modification Date:
2026-04-18 @ 1:17 PM
Study NCT ID:
NCT05799495
Status:
COMPLETED
Last Update Posted:
2024-10-09
First Post:
2023-04-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquires@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).', 'description': 'Same event may appear as both non-SAE and SAE but are distinct events. An event may be categorised as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE.', 'eventGroups': [{'id': 'EG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.', 'otherNumAtRisk': 40, 'deathsNumAtRisk': 40, 'otherNumAffected': 0, 'seriousNumAtRisk': 40, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.', 'otherNumAtRisk': 39, 'deathsNumAtRisk': 39, 'otherNumAffected': 1, 'seriousNumAtRisk': 39, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.', 'otherNumAtRisk': 79, 'deathsNumAtRisk': 79, 'otherNumAffected': 2, 'seriousNumAtRisk': 79, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.', 'otherNumAtRisk': 79, 'deathsNumAtRisk': 79, 'otherNumAffected': 4, 'seriousNumAtRisk': 79, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 79, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 79, 'numAffected': 4}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}], 'seriousEvents': [{'term': 'Supraventricular extrasystoles', 'stats': [{'groupId': 'EG000', 'numAtRisk': 40, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 79, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 79, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA v26.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5', 'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'OG000'}, {'value': '24', 'groupId': 'OG001'}, {'value': '66', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.883', 'groupId': 'OG000', 'lowerLimit': '-4.247', 'upperLimit': '-3.520'}, {'value': '-4.015', 'groupId': 'OG001', 'lowerLimit': '-4.452', 'upperLimit': '-3.578'}, {'value': '-4.380', 'groupId': 'OG002', 'lowerLimit': '-4.671', 'upperLimit': '-4.088'}, {'value': '-3.213', 'groupId': 'OG003', 'lowerLimit': '-3.517', 'upperLimit': '-2.908'}]}]}], 'analyses': [{'pValue': '0.0181', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-0.671', 'ciLowerLimit': '-1.080', 'ciUpperLimit': '-0.262', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.3178', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.0127', 'groupIds': ['OG001', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-0.802', 'ciLowerLimit': '-1.260', 'ciUpperLimit': '-0.344', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.3562', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '<.0001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-1.167', 'ciLowerLimit': '-1.506', 'ciUpperLimit': '-0.827', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.2640', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline (Day 1), Day 5', 'description': 'Change from baseline in SARS-CoV-2 RNA level at Day 5 was analyzed using Mixed Effects Repeated Measures (MMRM) model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\\<=3 versus \\[vs.\\] \\>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\\*log10 copies/milliliter, missing, or not detected.', 'unitOfMeasure': 'Log10 copies/milliliter', 'dispersionType': '80% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "The modified full analysis set (MFAS) included all participants in the full analysis set (FAS) who had SARS-CoV-2 RNA level greater than or equal to (\\>=) 4\\*log10 copies/mL at baseline. Participants were analyzed according to the study intervention to which they were randomized. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '70', 'groupId': 'OG002'}, {'value': '63', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'classes': [{'title': 'Day 3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '70', 'groupId': 'OG002'}, {'value': '63', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-2.006', 'groupId': 'OG000', 'lowerLimit': '-2.371', 'upperLimit': '-1.641'}, {'value': '-2.702', 'groupId': 'OG001', 'lowerLimit': '-3.123', 'upperLimit': '-2.280'}, {'value': '-2.546', 'groupId': 'OG002', 'lowerLimit': '-2.818', 'upperLimit': '-2.274'}, {'value': '-1.398', 'groupId': 'OG003', 'lowerLimit': '-1.684', 'upperLimit': '-1.112'}]}]}, {'title': 'Day 10', 'denoms': [{'units': 'Participants', 'counts': [{'value': '32', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '57', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-5.027', 'groupId': 'OG000', 'lowerLimit': '-5.326', 'upperLimit': '-4.728'}, {'value': '-5.085', 'groupId': 'OG001', 'lowerLimit': '-5.423', 'upperLimit': '-4.748'}, {'value': '-5.305', 'groupId': 'OG002', 'lowerLimit': '-5.529', 'upperLimit': '-5.082'}, {'value': '-5.091', 'groupId': 'OG003', 'lowerLimit': '-5.332', 'upperLimit': '-4.851'}]}]}, {'title': 'Day 14', 'denoms': [{'units': 'Participants', 'counts': [{'value': '34', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '68', 'groupId': 'OG002'}, {'value': '61', 'groupId': 'OG003'}]}], 'categories': [{'measurements': [{'value': '-5.682', 'groupId': 'OG000', 'lowerLimit': '-5.913', 'upperLimit': '-5.451'}, {'value': '-5.500', 'groupId': 'OG001', 'lowerLimit': '-5.769', 'upperLimit': '-5.231'}, {'value': '-5.826', 'groupId': 'OG002', 'lowerLimit': '-6.009', 'upperLimit': '-5.643'}, {'value': '-5.443', 'groupId': 'OG003', 'lowerLimit': '-5.637', 'upperLimit': '-5.250'}]}]}], 'analyses': [{'pValue': '0.0378', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-0.608', 'ciLowerLimit': '-1.046', 'ciUpperLimit': '-0.170', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.3402', 'groupDescription': 'Day 3', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.0003', 'groupIds': ['OG001', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-1.304', 'ciLowerLimit': '-1.782', 'ciUpperLimit': '-0.826', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.3718', 'groupDescription': 'Day 3', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '<.0001', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-1.148', 'ciLowerLimit': '-1.509', 'ciUpperLimit': '-0.788', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.2803', 'groupDescription': 'Day 3', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.5931', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '0.064', 'ciLowerLimit': '-0.287', 'ciUpperLimit': '0.416', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.2732', 'groupDescription': 'Day 10', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.5080', 'groupIds': ['OG001', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '0.006', 'ciLowerLimit': '-0.369', 'ciUpperLimit': '0.381', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.2914', 'groupDescription': 'Day 10', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.1692', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-0.214', 'ciLowerLimit': '-0.501', 'ciUpperLimit': '0.073', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.2230', 'groupDescription': 'Day 10', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.1172', 'groupIds': ['OG000', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-0.239', 'ciLowerLimit': '-0.497', 'ciUpperLimit': '0.019', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.2004', 'groupDescription': 'Day 14', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.3979', 'groupIds': ['OG001', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-0.056', 'ciLowerLimit': '-0.337', 'ciUpperLimit': '0.224', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.2178', 'groupDescription': 'Day 14', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}, {'pValue': '0.0109', 'groupIds': ['OG002', 'OG003'], 'paramType': 'LS Mean difference', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-0.383', 'ciLowerLimit': '-0.595', 'ciUpperLimit': '-0.170', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.1655', 'groupDescription': 'Day 14', 'statisticalMethod': 'Mixed Models Analysis', 'nonInferiorityType': 'OTHER'}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline (Day 1), Day 3, Day 10 and Day 14', 'description': 'Change from baseline in SARS-CoV-2 RNA level at Day 3, Day 10 and Day 14 were analyzed using MMRM model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\\<=3 vs. \\>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\\*log10 copies/milliliter, missing, or not detected.', 'unitOfMeasure': 'Log10 copies/milliliter', 'dispersionType': '80% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "The MFAS included all participants in the FAS who had SARS-CoV-2 RNA level \\>= 4\\*log10 copies/mL at baseline. Participants were analyzed according to the study intervention to which they were randomized. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. 'Number Analyzed' signifies number of participants evaluable for the specified rows."}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '79', 'groupId': 'OG002'}, {'value': '79', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'classes': [{'title': 'TEAEs', 'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '11', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)', 'description': 'An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. An SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety analysis set (SAS) included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuations', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '79', 'groupId': 'OG002'}, {'value': '79', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'classes': [{'title': 'Discontinuations from study due to TEAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Permanent discontinuations from study intervention due to TEAEs', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)', 'description': 'An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. Participants with an AE record indicating the AE caused permanent discontinuation from the study were reported under discontinuations from study due to TEAEs. Permanent discontinuations from study intervention due to TEAEs included those participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The SAS included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With Laboratory Test Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '78', 'groupId': 'OG002'}, {'value': '77', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '13', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).', 'description': 'The following laboratory parameters were assessed according to pre-specified criteria for abnormalities: a) hematology; hemoglobin (gram per deciliter \\[g/dL\\]), (less than\\[\\<\\]0.8\\*lower limit of normal \\[LLN\\]), erythrocytes(10\\^12/Liter \\[L\\])(\\< 0.8\\*LLN), lymphocytes(10\\^9/L)(more than\\[\\>\\]1.2\\*upper limit of normal \\[ULN\\]), neutrophils(\\> 1.2\\*ULN and \\< 0.8\\*LLN), basophils(10\\^9/L)(\\> 1.2\\*ULN) and eosinophils (10\\^9/L)(\\> 1.2\\*ULN). b) clinical chemistry; bilirubin(mg/dL)(\\> 1.5\\*ULN), urea nitrogen(mg/dL)(\\> 1.3\\*ULN), creatinine(mg/dL)(\\> 1.3\\*ULN), potassium(milli equivalence per millilitre \\[mEq/L\\], (\\< 0.9\\*LLN and \\> 1.1\\*ULN), calcium (mg/dL)(\\< 0.9\\*LLN), bicarbonate(mEq/L)(\\< 0.9\\*LLN and \\> 1.1\\*ULN), glucose (mg/dL)(\\> 1.5\\*ULN), creatine kinase(units per litre \\[U/L) (\\> 2.0\\* ULN), D-Dimer(nanogram per milliliter\\[ng/mL\\]), (\\>1.5\\*ULN) and c)urinalysis; bacteria (low power field \\[LPF\\]\\>20). Number of participants with any laboratory abnormalities meeting pre-specified criteria are reported in this outcome measure.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "The SAS included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Number of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '78', 'groupId': 'OG002'}, {'value': '77', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'classes': [{'title': 'Systolic blood pressure; value < 90 (mmHg)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}]}]}, {'title': 'Systolic blood pressure; change >= 30 (mmHg) increase', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Systolic blood pressure; change >= 30 (mmHg) decrease', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '3', 'groupId': 'OG003'}]}]}, {'title': 'Diastolic blood pressure; value <50 (mmHg)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Diastolic blood pressure; change >= 20 (mmHg) increase', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}]}]}, {'title': 'Diastolic blood pressure; change >= 20 (mmHg) decrease', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}]}]}, {'title': 'Pulse rate; value < 40 (bpm)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'Pulse rate; value > 120 (bpm)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).', 'description': 'Vital signs included blood pressure and pulse rate and were assessed with the participant in the supine or seated position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Pre-defined criteria for vital sign abnormalities was as systolic blood pressure (millimeter of mercury \\[mmHg\\]): value \\< 90, change \\>= 30 increase and change \\>= 30 decrease, diastolic blood pressure (mmHg): value \\<50; change \\>= 20 increase and change \\>= 20 decrease, pulse rate (beats per minute \\[bpm\\]): value \\< 40 and value \\> 120.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "The SAS included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}, {'type': 'SECONDARY', 'title': 'Number of Participants Meeting Pre-defined Criteria For ECG Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '79', 'groupId': 'OG002'}, {'value': '78', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'OG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'classes': [{'title': 'PR Interval, value >= 280 (msec)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'PR Interval, change > 40 increase (msec)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'QT Interval (msec) value >500', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'QTcF Interval, 450 < value =< 480 (msec)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '6', 'groupId': 'OG003'}]}]}, {'title': 'QTCF Interval, 480 < value =< 500 (msec)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'QTCF Interval, value > 500 (msec)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}, {'title': 'QTCF Interval, 30 < change <= 60 increase (msec)', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}]}]}, {'title': 'QTCF Interval, change > 60 increase (msec)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From baseline (Day 1) up to Day 10', 'description': 'Twelve lead ECGs were collected using an ECG machine that automatically calculated heart rate and measured PR interval, QT interval, and QT interval correct by Frederica formula (QTcF). ECG abnormalities included: PR interval (millisecond \\[msec\\]): value \\>=280, change \\>40 increase; QT interval aggregate (msec): value \\> 500), QTcF interval (450 \\< value =\\< 480; 480 \\< value =\\< 500; value \\> 500; 30 \\< change \\<= 60 increase and change \\> 60 increase).', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': "The SAS included all participants randomly assigned to study intervention and who have taken at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received. Here 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 milligrams (mg) orally every 12 hours (q12h) for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'FG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'FG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'FG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}], 'periods': [{'title': 'Treatment (Up to 5 Days)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '40'}, {'groupId': 'FG001', 'numSubjects': '40'}, {'groupId': 'FG002', 'numSubjects': '80'}, {'groupId': 'FG003', 'numSubjects': '80'}]}, {'type': 'Treated', 'achievements': [{'groupId': 'FG000', 'numSubjects': '40'}, {'groupId': 'FG001', 'numSubjects': '39'}, {'groupId': 'FG002', 'numSubjects': '79'}, {'groupId': 'FG003', 'numSubjects': '79'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '39'}, {'groupId': 'FG001', 'numSubjects': '36'}, {'groupId': 'FG002', 'numSubjects': '77'}, {'groupId': 'FG003', 'numSubjects': '75'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '5'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Non-compliance with study drug', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '3'}]}, {'type': 'Randomized not treated', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}]}]}, {'title': 'Follow Up (Up to 4 Weeks)', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '39'}, {'comment': 'Eligible participants who discontinued study intervention could enter follow-up.', 'groupId': 'FG001', 'numSubjects': '37'}, {'comment': 'Eligible participants who discontinued study intervention could enter follow-up.', 'groupId': 'FG002', 'numSubjects': '78'}, {'comment': 'Eligible participants who discontinued study intervention could enter follow-up.', 'groupId': 'FG003', 'numSubjects': '76'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '39'}, {'groupId': 'FG001', 'numSubjects': '37'}, {'groupId': 'FG002', 'numSubjects': '77'}, {'groupId': 'FG003', 'numSubjects': '76'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}]}]}], 'preAssignmentDetails': 'A total of 278 participants were screened, of which 37 failed screening and 1 participant was not randomized due to investigational product shortage at site. A total of 240 participants were randomized and assigned to study intervention.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'BG000'}, {'value': '39', 'groupId': 'BG001'}, {'value': '79', 'groupId': 'BG002'}, {'value': '79', 'groupId': 'BG003'}, {'value': '237', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'PF-07817883 100mg', 'description': 'Participants received PF-07817883, 100 mg orally q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'BG001', 'title': 'PF-07817883 300mg', 'description': 'Participants received PF-07817883, 300 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'BG002', 'title': 'PF-07817883 600mg', 'description': 'Participants received PF-07817883, 600 mg orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'BG003', 'title': 'Placebo', 'description': 'Participants received placebo orally every q12h for 5 days (10 doses total). Participants were followed up for 4 weeks.'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.6', 'spread': '12.30', 'groupId': 'BG000'}, {'value': '41.9', 'spread': '11.31', 'groupId': 'BG001'}, {'value': '41.4', 'spread': '11.60', 'groupId': 'BG002'}, {'value': '41.5', 'spread': '12.97', 'groupId': 'BG003'}, {'value': '41.9', 'spread': '12.10', 'groupId': 'BG004'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '50', 'groupId': 'BG002'}, {'value': '45', 'groupId': 'BG003'}, {'value': '147', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '17', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '29', 'groupId': 'BG002'}, {'value': '34', 'groupId': 'BG003'}, {'value': '90', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '35', 'groupId': 'BG000'}, {'value': '31', 'groupId': 'BG001'}, {'value': '63', 'groupId': 'BG002'}, {'value': '64', 'groupId': 'BG003'}, {'value': '193', 'groupId': 'BG004'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '5', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}, {'value': '15', 'groupId': 'BG003'}, {'value': '43', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '11', 'groupId': 'BG004'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '20', 'groupId': 'BG004'}]}, {'title': 'White', 'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '35', 'groupId': 'BG001'}, {'value': '60', 'groupId': 'BG002'}, {'value': '69', 'groupId': 'BG003'}, {'value': '203', 'groupId': 'BG004'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}, {'value': '2', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'The full analysis set (FAS) included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention Participants were analyzed according to the intervention they were actually randomized.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-04-14', 'size': 668056, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2024-09-12T10:49', 'hasProtocol': True}, {'date': '2023-05-12', 'size': 474219, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2024-09-12T10:49', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 240}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-05-23', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-09', 'completionDateStruct': {'date': '2023-10-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-09-12', 'studyFirstSubmitDate': '2023-04-04', 'resultsFirstSubmitDate': '2024-09-12', 'studyFirstSubmitQcDate': '2023-04-04', 'lastUpdatePostDateStruct': {'date': '2024-10-09', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-09-12', 'studyFirstPostDateStruct': {'date': '2023-04-05', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-10-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-09-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in Logarithm Base 10 (Log10) Transformed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Ribo Nucleic Acid (RNA) Level on Day 5', 'timeFrame': 'Baseline (Day 1), Day 5', 'description': 'Change from baseline in SARS-CoV-2 RNA level at Day 5 was analyzed using Mixed Effects Repeated Measures (MMRM) model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\\<=3 versus \\[vs.\\] \\>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\\*log10 copies/milliliter, missing, or not detected.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in Log10 Transformed SARS-CoV-2 RNA Level on Days 3, 10 and 14', 'timeFrame': 'Baseline (Day 1), Day 3, Day 10 and Day 14', 'description': 'Change from baseline in SARS-CoV-2 RNA level at Day 3, Day 10 and Day 14 were analyzed using MMRM model with fixed effects including treatment, visit, visit by treatment interaction, and baseline viral load. Covariates included days from baseline since symptom onset (\\<=3 vs. \\>3 days), vaccination status (complete or partial vs. unvaccinated), baseline anti-N serology status and age at screening (years). Participants were excluded from the analysis if baseline viral load was less than 4\\*log10 copies/milliliter, missing, or not detected.'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)', 'description': 'An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. An SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event.'}, {'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuations', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days)', 'description': 'An AE was any untoward medical occurrence in a study participant after administration of a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An adverse event is considered a treatment-emergent adverse event (TEAE) if the event started on or after the study medication start date and time. Participants with an AE record indicating the AE caused permanent discontinuation from the study were reported under discontinuations from study due to TEAEs. Permanent discontinuations from study intervention due to TEAEs included those participants who had an AE record that indicated that action taken with study treatment was drug withdrawn but AE did not cause the participant to be discontinued from study.'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).', 'description': 'The following laboratory parameters were assessed according to pre-specified criteria for abnormalities: a) hematology; hemoglobin (gram per deciliter \\[g/dL\\]), (less than\\[\\<\\]0.8\\*lower limit of normal \\[LLN\\]), erythrocytes(10\\^12/Liter \\[L\\])(\\< 0.8\\*LLN), lymphocytes(10\\^9/L)(more than\\[\\>\\]1.2\\*upper limit of normal \\[ULN\\]), neutrophils(\\> 1.2\\*ULN and \\< 0.8\\*LLN), basophils(10\\^9/L)(\\> 1.2\\*ULN) and eosinophils (10\\^9/L)(\\> 1.2\\*ULN). b) clinical chemistry; bilirubin(mg/dL)(\\> 1.5\\*ULN), urea nitrogen(mg/dL)(\\> 1.3\\*ULN), creatinine(mg/dL)(\\> 1.3\\*ULN), potassium(milli equivalence per millilitre \\[mEq/L\\], (\\< 0.9\\*LLN and \\> 1.1\\*ULN), calcium (mg/dL)(\\< 0.9\\*LLN), bicarbonate(mEq/L)(\\< 0.9\\*LLN and \\> 1.1\\*ULN), glucose (mg/dL)(\\> 1.5\\*ULN), creatine kinase(units per litre \\[U/L) (\\> 2.0\\* ULN), D-Dimer(nanogram per milliliter\\[ng/mL\\]), (\\>1.5\\*ULN) and c)urinalysis; bacteria (low power field \\[LPF\\]\\>20). Number of participants with any laboratory abnormalities meeting pre-specified criteria are reported in this outcome measure.'}, {'measure': 'Number of Participants Meeting Pre-defined Criteria of Vital Sign Abnormalities', 'timeFrame': 'From start of study intervention up to 28 days after last dose of study intervention (up to 33 days).', 'description': 'Vital signs included blood pressure and pulse rate and were assessed with the participant in the supine or seated position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Pre-defined criteria for vital sign abnormalities was as systolic blood pressure (millimeter of mercury \\[mmHg\\]): value \\< 90, change \\>= 30 increase and change \\>= 30 decrease, diastolic blood pressure (mmHg): value \\<50; change \\>= 20 increase and change \\>= 20 decrease, pulse rate (beats per minute \\[bpm\\]): value \\< 40 and value \\> 120.'}, {'measure': 'Number of Participants Meeting Pre-defined Criteria For ECG Abnormalities', 'timeFrame': 'From baseline (Day 1) up to Day 10', 'description': 'Twelve lead ECGs were collected using an ECG machine that automatically calculated heart rate and measured PR interval, QT interval, and QT interval correct by Frederica formula (QTcF). ECG abnormalities included: PR interval (millisecond \\[msec\\]): value \\>=280, change \\>40 increase; QT interval aggregate (msec): value \\> 500), QTcF interval (450 \\< value =\\< 480; 480 \\< value =\\< 500; value \\> 500; 30 \\< change \\<= 60 increase and change \\> 60 increase).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['COVID-19', 'SARS COVID-19'], 'conditions': ['SARS-CoV-2 Infection']}, 'referencesModule': {'references': [{'pmid': '39486089', 'type': 'DERIVED', 'citation': 'Mortezavi M, Sloan A, Singh RSP, Chen LF, Kim JH, Shojaee N, Toussi SS, Prybylski J, Baniecki ML, Bergman A, Banerjee A, Allerton C, Alami NN. Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19. Clin Infect Dis. 2025 Mar 17;80(3):673-680. doi: 10.1093/cid/ciae529.'}], 'seeAlsoLinks': [{'url': 'https://pmiform.com/clinical-trial-info-request?StudyID=C5091003', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': "The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19. To understand that samples are collected from adult participants who have the symptoms of COVID 19 but are not hospitalized.\n\nThe study is seeking for participants who:\n\n* are 18 years of age or older at the time of entering the study.\n* have a positive rapid antigen test within 48 hours before entering the study. Rapid antigen test is a test done to confirm the presence of a specific virus in the body.\n* have onset of signs or symptoms of COVID-19 within 5 days before entering the study.\n* have at least 1 of the specified signs or symptoms of COVID-19 present on the day of entering the study.\n\nAround 228 participants with a confirmed case of COVID 19 are planned to be taken into the study. Participants will be randomly grouped to receive PF-07817883. Three groups will receive 100, 300, 600mg of PF-07817883 and one of the groups will receive placebo (a pill that doesn't have any medicines) orally every 12 hours for 5 days.\n\nThe study is going to last up to 5 weeks. This includes the initial period of selecting participants, participants receiving the medicine or the placebo and then a 4-week follow-up period after giving the participants the last medicine.\n\nThe study team will monitor how each participant is doing with the study treatment during the study."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '64 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Participants ≥18 to \\<65 years of age at the time of the Screening Visit.\n\n * WOCBP may be enrolled.\n * All fertile participants must agree to use a highly effective method of contraception.\n2. Confirmed SARS-CoV-2 infection as determined by RAT in NP specimen collected within 48 hours prior to randomization. Investigator sites will use test kits that are authorized for use in this study and the test result must be available to confirm eligibility.\n3. Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified signs/symptoms attributable to COVID-19 present on the day of randomization.\n\nExclusion Criteria:\n\n1. Current need for hospitalization or anticipated need for hospitalization within 24h after randomization in the clinical opinion of the site investigator.\n2. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh Class B or Class C, or acute liver failure.\n3. History of hypersensitivity or other contraindication to any of the components of the study interventions, as determined by the investigator.\n4. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.\n5. Immunocompromised with ≥1 of the following:\n\n 1. Solid organ (eg, liver, heart, lung or kidney) transplant recipient who is receiving immunosuppressive therapy.\n 2. Receipt of CAR-T-cell therapy or HCT either within 2 years of transplantation or receiving immunosuppressive therapy.\n 3. Moderate or severe primary immunodeficiency (eg, DiGeorge syndrome, Wiskott-Aldrich syndrome).\n 4. Use of at least 1 of the following immune-weakening medications:\n\n iii. Has received corticosteroids equivalent to prednisone ≥20 mg daily for at least 14 consecutive days within 30 days prior to study entry.\n\n iv. Active treatment causing significant immunosuppression, including alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents, TNF blockers, or other highly immunosuppressive drugs such as biologics.\n 5. Hematological malignancy (including leukemia, lymphoma and myeloma) or active immunosuppressive treatment for solid tumor.\n 6. HIV infection with CD4 cell count \\<200 mm3 from known medical history within the past 6 months of screening.\n6. known severe renal impairment (eGFR of \\<30 mL/min/1.73 m2 within 6 months of the screening visit, using the serum creatinine-based CKD-EPI formula12).\n7. Oxygen saturation of \\<92% on room air obtained at rest within 24h prior to randomization.\n8. Has received or is expected to receive any other antiviral for the treatment of COVID 19, including remdesivir, PAXLOVID, molnupiravir, mAb treatment (within 30 days or 5 half-lives \\[whichever is longer\\] prior to screening) or received convalescent COVID-19 plasma within 12 months.\n9. Expected to receive any dose of a SARS-CoV-2 vaccine within 14 days of randomization or during the study.\n10. Current or previous administration with an investigational product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Authorized or products with conditional approval are not considered investigational.\n11. Known prior participation in this trial\n12. Known history of any of the following abnormalities in clinical laboratory tests (within past 6 months of the screening visit):\n\n * T bili ≥2 × ULN (except for Gilbert's syndrome)\n * AST or ALT ≥2.5 × ULN\n * Abs neutrophil count \\<1000/mm3."}, 'identificationModule': {'nctId': 'NCT05799495', 'briefTitle': 'A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF-07817883 IN NON-HOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19', 'orgStudyIdInfo': {'id': 'C5091003'}, 'secondaryIdInfos': [{'id': '2022-002871-12', 'type': 'EUDRACT_NUMBER'}, {'id': '2023-506667-34-00', 'type': 'CTIS'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Arm 1: low dose', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 2: medium dose', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'EXPERIMENTAL', 'label': 'Arm 3: high dose', 'interventionNames': ['Drug: PF-07817883']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Arm 4: Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'PF-07817883', 'type': 'DRUG', 'description': 'Arm 1: low dose Arm 2: medium dose Arm 3: high dose', 'armGroupLabels': ['Arm 1: low dose', 'Arm 2: medium dose', 'Arm 3: high dose']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo', 'armGroupLabels': ['Arm 4: Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35055', 'city': 'Cullman', 'state': 'Alabama', 'country': 'United States', 'facility': 'Cullman Clinical Trials', 'geoPoint': {'lat': 34.17482, 'lon': -86.84361}}, {'zip': '85004', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': 'ClinMed', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '85378', 'city': 'Surprise', 'state': 'Arizona', 'country': 'United States', 'facility': 'Epic Medical Research - Surprise', 'geoPoint': {'lat': 33.63059, 'lon': -112.33322}}, {'zip': '72212', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Applied Research Center of Arkansas', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '93301', 'city': 'Bakersfield', 'state': 'California', 'country': 'United States', 'facility': 'Franco Felizarta, Md', 'geoPoint': {'lat': 35.37329, 'lon': -119.01871}}, {'zip': '91303', 'city': 'Canoga Park', 'state': 'California', 'country': 'United States', 'facility': 'Hope Clinical Research, Inc.', 'geoPoint': {'lat': 34.20112, 'lon': -118.59814}}, {'zip': '91911', 'city': 'Chula Vista', 'state': 'California', 'country': 'United States', 'facility': 'Velocity Clinical Research, Chula Vista', 'geoPoint': {'lat': 32.64005, 'lon': -117.0842}}, {'zip': '92324', 'city': 'Colton', 'state': 'California', 'country': 'United States', 'facility': 'Benchmark Research', 'geoPoint': {'lat': 34.0739, 'lon': -117.31365}}, {'zip': '92835', 'city': 'Fullerton', 'state': 'California', 'country': 'United States', 'facility': 'Ascada Health PC dba Ascada Research', 'geoPoint': {'lat': 33.87029, 'lon': -117.92534}}, {'zip': '90806', 'city': 'Long Beach', 'state': 'California', 'country': 'United States', 'facility': 'Long Beach Clinical Trials', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '92704', 'city': 'Santa Ana', 'state': 'California', 'country': 'United States', 'facility': 'Marvel Clinical Research - Santa Ana', 'geoPoint': {'lat': 33.74557, 'lon': -117.86783}}, {'zip': '33134', 'city': 'Coral Gables', 'state': 'Florida', 'country': 'United States', 'facility': 'Herco Medical and Research Center Inc', 'geoPoint': {'lat': 25.72149, 'lon': -80.26838}}, {'zip': '33157', 'city': 'Cutler Bay', 'state': 'Florida', 'country': 'United States', 'facility': 'Advance Clinical Research Group', 'geoPoint': {'lat': 25.5783, 'lon': -80.3377}}, {'zip': '33308', 'city': 'Fort Lauderdale', 'state': 'Florida', 'country': 'United States', 'facility': 'Proactive Clinical Research,LLC', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'zip': '33010', 'city': 'Hialeah', 'state': 'Florida', 'country': 'United States', 'facility': 'Qway Research LLC', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'zip': '33018', 'city': 'Hialeah Gardens', 'state': 'Florida', 'country': 'United States', 'facility': 'Unlimited Medical Research Group LLC', 'geoPoint': {'lat': 25.8651, 'lon': -80.3245}}, {'zip': '33122', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Angels Clinical Research Institute', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33135', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'South Florida Research Center', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33143', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'USPA Advance Concept Medical Research Group', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33144', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Bio-Medical Research LLC', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33186', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Coral Research Clinic Corp', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33014', 'city': 'Miami Lakes', 'state': 'Florida', 'country': 'United States', 'facility': 'Palm Springs Community Health Center', 'geoPoint': {'lat': 25.90871, 'lon': -80.30866}}, {'zip': '33029', 'city': 'Pembroke Pines', 'state': 'Florida', 'country': 'United States', 'facility': 'DBC Research USA', 'geoPoint': {'lat': 26.00315, 'lon': -80.22394}}, {'zip': '33705', 'city': 'St. Petersburg', 'state': 'Florida', 'country': 'United States', 'facility': 'GCP Research, Global Clinical professionals', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'zip': '31707', 'city': 'Albany', 'state': 'Georgia', 'country': 'United States', 'facility': 'Javara - Privia Medical Group Georgia - Albany', 'geoPoint': {'lat': 31.57851, 'lon': -84.15574}}, {'zip': '31904', 'city': 'Columbus', 'state': 'Georgia', 'country': 'United States', 'facility': 'Centricity Research Columbus Georgia Multispecialty', 'geoPoint': {'lat': 32.46098, 'lon': -84.98771}}, {'zip': '31909', 'city': 'Columbus', 'state': 'Georgia', 'country': 'United States', 'facility': 'Centricity Research Columbus Acute Care', 'geoPoint': {'lat': 32.46098, 'lon': -84.98771}}, {'zip': '30291', 'city': 'Union City', 'state': 'Georgia', 'country': 'United States', 'facility': 'Rophe Adult and Pediatric Medicine/SKYCRNG', 'geoPoint': {'lat': 33.58706, 'lon': -84.54243}}, {'zip': '83404', 'city': 'Idaho Falls', 'state': 'Idaho', 'country': 'United States', 'facility': 'Snake River Research', 'geoPoint': {'lat': 43.46658, 'lon': -112.03414}}, {'zip': '01655', 'city': 'Worcester', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'University of Massachusetts Chan Medical School', 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}}, {'zip': '48706', 'city': 'Bay City', 'state': 'Michigan', 'country': 'United States', 'facility': 'Great Lakes Research Group, Inc.', 'geoPoint': {'lat': 43.59447, 'lon': -83.88886}}, {'zip': '59701', 'city': 'Butte', 'state': 'Montana', 'country': 'United States', 'facility': 'Mercury Street Medical Group, PLLC', 'geoPoint': {'lat': 46.00382, 'lon': -112.53474}}, {'zip': '89052', 'city': 'Henderson', 'state': 'Nevada', 'country': 'United States', 'facility': 'Henderson Clinical Trials', 'geoPoint': {'lat': 36.0397, 'lon': -114.98194}}, {'zip': '89109', 'city': 'Las Vegas', 'state': 'Nevada', 'country': 'United States', 'facility': 'Excel Clinical Research, LLC', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '28112', 'city': 'Monroe', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Monroe Biomedical Research', 'geoPoint': {'lat': 34.98543, 'lon': -80.54951}}, {'zip': '28401', 'city': 'Wilmington', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Accellacare - Wilmington', 'geoPoint': {'lat': 34.23556, 'lon': -77.94604}}, {'zip': '45215', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Wellnow Urgent Care and Research', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '43215', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Remington-Davis, Inc', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '45424', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'WellNow Urgent Care & Research', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '29640', 'city': 'Easley', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Kur Research @ Bon Secours Mercy Health, Inc - Urgent Care Easley', 'geoPoint': {'lat': 34.82984, 'lon': -82.60152}}, {'zip': '77384', 'city': 'Conroe', 'state': 'Texas', 'country': 'United States', 'facility': 'Javara - Privia Medical Group Gulf Coast - The Woodlands PGTW', 'geoPoint': {'lat': 30.31188, 'lon': -95.45605}}, {'zip': '77433', 'city': 'Cypress', 'state': 'Texas', 'country': 'United States', 'facility': 'Javara - Privia Medical Group Gulf Coast - Cypress', 'geoPoint': {'lat': 29.96911, 'lon': -95.69717}}, {'zip': '75234', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'DFW Clinical Research', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '78539', 'city': 'Edinburg', 'state': 'Texas', 'country': 'United States', 'facility': 'Proactive Clinical Research LLC', 'geoPoint': {'lat': 26.30174, 'lon': -98.16334}}, {'zip': '77057', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Next Level Urgent Care', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78041', 'city': 'Laredo', 'state': 'Texas', 'country': 'United States', 'facility': 'Laguna Clinical Research', 'geoPoint': {'lat': 27.50641, 'lon': -99.50754}}, {'zip': '75057', 'city': 'Lewisville', 'state': 'Texas', 'country': 'United States', 'facility': 'Epic Clinical Research', 'geoPoint': {'lat': 33.04623, 'lon': -96.99417}}, {'zip': '78249', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'BFHC Research, LLC', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '78231', 'city': 'Shavano Park', 'state': 'Texas', 'country': 'United States', 'facility': 'Consano Clinical Research, LLC', 'geoPoint': {'lat': 29.58495, 'lon': -98.55252}}, {'zip': '77384', 'city': 'Shenandoah', 'state': 'Texas', 'country': 'United States', 'facility': 'Javara - Privia Medical Group Gulf Coast - The Woodlands PGTW', 'geoPoint': {'lat': 30.18022, 'lon': -95.45577}}, {'zip': '76401', 'city': 'Stephenville', 'state': 'Texas', 'country': 'United States', 'facility': 'Javara - Privia Medical Group North Texas - Stephenville', 'geoPoint': {'lat': 32.2207, 'lon': -98.20226}}, {'zip': '77384', 'city': 'The Woodlands', 'state': 'Texas', 'country': 'United States', 'facility': 'Javara - Privia Medical Group Gulf Coast - The Woodlands PGTW', 'geoPoint': {'lat': 30.15799, 'lon': -95.48938}}, {'zip': '98052', 'city': 'Redmond', 'state': 'Washington', 'country': 'United States', 'facility': 'Eastside Research Associates', 'geoPoint': {'lat': 47.67399, 'lon': -122.12151}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'ipdSharingStatementModule': {'url': 'https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests', 'ipdSharing': 'YES', 'description': "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}